Abstract:Therapeutic protein production in plants is an area of great potential for increasing and improving the production of proteins for the treatment or prevention of disease in humans and other animals. There are a number of key benefits of this technique for scientists and society, as well as regulatory challenges that need to be overcome by policymakers. Increased public understanding of the costs and benefits of therapeutic protein production in plants will be instrumental in increasing the acceptance, and thus the medical and veterinary impact, of this approach. Therapeutic recombinant proteins are a powerful tool for combating many diseases which have previously been hard to treat. The most utilized expression systems are Chinese Hamster Ovary cells and Escherichia coli, but all available expression systems have strengths and weaknesses regarding development time, cost, protein size, yield, growth conditions, posttranslational modifications and regulatory approval. The plant industry is well established and growing and harvesting crops is easy and affordable using current infrastructure. Growth conditions are generally simple: sunlight, water, and the addition of cheap, available fertilizers. There are multiple options for plant expression systems, including species, genetic constructs and protein targeting, each best suited to a particular type of therapeutic protein production. Transient expression systems provide a mechanism to rapidly transfect plants and produce therapeutic protein in a matter of weeks, rather than the months it can take for many competing expression systems, while proteins targeted to cereal seeds can be harvested, stored and potentially purified much more easily than in competing systems. Current challenges for plant expression systems include a lack of regulatory approval, environmental containment concerns and nonhuman glycosylation, which may limit the scope of the type of therapeutic proteins that can be manufactured in plants. The specific strengths of plant expression systems could facilitate the production of certain therapeutic proteins quickly and cheaply in the near future. Therapeutic protein production in plants is an area of great potential for increasing and improving the production of proteins for the treatment or prevention of disease in humans and other animals. There are a number of key benefits of this technique for scientists and society, as well as regulatory challenges that need to be overcome by policymakers. Increased public understanding of the costs and benefits of therapeutic protein production in plants will be instrumental in increasing the acceptance, and thus the medical and veterinary impact, of this approach.

Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement

Engineering of Therapeutic Proteins Production in Escherichia coli

Cellular engineering of plant cells for improved therapeutic protein production

Biopharmaceutical Protein Production by Saccharomyces Cerevisiae: Current State and Future Prospects

Mammalian Cell Protein Expression for Biopharmaceutical Production

Strategies to enhance productivity and modify product quality in therapeutic proteins

Engineering Saccharomyces Cerevisiae for Efficient Production of Recombinant Proteins

Engineering cell physiology to enhance recombinant protein production in Escherichia coli

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Current trends in biopharmaceuticals production in Escherichia coli

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing

Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering

Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review

Genetic engineering modification and fermentation optimization for extracellular production of recombinant proteins using Escherichia coli

Extracellular recombinant protein production from Escherichia coli

Integrating Computational Design and Experimental Approaches for Next-Generation Biologics

Therapeutic recombinant protein production in plants: Challenges and opportunities

Recent progress in therapeutic natural product biosynthesis using Escherichia coli

A cell‐free expression and purification process for rapid production of protein biologics

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies